Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis

Next Previous
Trial Profile

An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors TG Therapeutics

Most Recent Events

  • 10 Sep 2025 According to a TG Therapeutics Inc media release, company announced upcoming schedule of presentations highlighting BRIUMVI at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 24 - 26, 2025 in Barcelona, Spain.
  • 10 Apr 2025 According to a TG Therapeutics Inc media release, company presented result data from this study at the American Academy of Neurology 2025 annual meeting.
  • 07 Mar 2025 According to a TG Therapeutics Inc media release, data from this study presented at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top